Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration

This publication has 26 references indexed in Scilit:

• Do the Results of Randomized Clinical Trials of Cardiovascular Drugs Influence Medical Practice?
  New England Journal of Medicine, 1992
• Adjunctive use of beta-adrenergic blockers, calcium antagonists and other therapies in coronary thrombolysis
  The American Journal of Cardiology, 1991
• Verapamil inhibits serotonin uptake of endothelial cells in culture by a mechanism unrelated to Ca²⁺ channel blockade
  Journal of Cellular Physiology, 1987
• Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome
  The American Journal of Cardiology, 1987
• Effects of nifedipine on platelet function
  American Heart Journal, 1985
• Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.
  Circulation, 1985
• Verapamil, an antagonist at 5-Hydroxytryptamine receptors of human blood platelets
  European Journal of Pharmacology, 1985
• Effects of oral diltiazem in paroxysmal supraventricular tachycardia
  The American Journal of Cardiology, 1983
• Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs
  The American Journal of Cardiology, 1983
• Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin
  Biochemical and Biophysical Research Communications, 1982